A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
Hyo Sik JangGalen HostetterAlexander W MacFarlaneZachary B MadajEric A RossToshinori HinoueJustin R KulchyckiRyan S BurgosMahvish TafseerR Katherine AlpaughCandice L SchwebelRutika KokateDaniel M GeynismanMatthew R ZibelmanPooja GhataliaPeter W NicholsWoonbok ChungJozef MadzoNoah M HahnDavid I QuinnJean-Pierre J IssaMichael J TopperStephen B BaylinHui ShenKerry S CampbellPeter A JonesElizabeth R PlimackPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
No RECIST responses were observed after combination therapy in this trial. Although we could not detect the anticipated tumor-intrinsic effects of guadecitabine, the addition of hypomethylating agent to ICI therapy induced immune activation in a few patients, which associated with longer patient survival.
Keyphrases
- combination therapy
- end stage renal disease
- newly diagnosed
- ejection fraction
- squamous cell carcinoma
- small cell lung cancer
- clinical trial
- peritoneal dialysis
- prognostic factors
- study protocol
- randomized controlled trial
- stem cells
- diabetic rats
- open label
- mesenchymal stem cells
- phase ii
- patient reported outcomes
- high glucose
- oxidative stress
- cell therapy
- smoking cessation